SCHEMBL16886159

SCHEMBL16886159

Cc1ccc(COc2cc(F)cc(Oc3ccc(-c4nn(C5CCOCC5)c5ncnc(N)c45)cc3F)c2)s1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 14/20 0.49
▸ EGFR P00533 14/20 0.49
▸ SRC P12931 14/20 0.49
▸ ABL1 P00519 12/20 0.49
▸ HCK P08631 12/20 0.49
▸ KDR P35968 12/20 0.49
▸ PIK3CA P42336 12/20 0.49
▸ PIK3CB P42338 12/20 0.49
▸ MTOR P42345 12/20 0.49
▸ PIK3CG P48736 12/20 0.49
▸ EPHB4 P54760 12/20 0.49
▸ PRKDC P78527 12/20 0.49
▸ PI4KB Q9UBF8 10/20 0.49
▸ BTK Q06187 2/20 0.46
▸ IGF1R P08069 1/20 0.45
▸ LCK P06239 2/20 0.45
▸ CSK P41240 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16886167 0.93 CSNK1A1 (0.51) PIK3CDEGFRSRCABL1HCK
SCHEMBL15613752 0.92 PIK3CD (0.48) PIK3CDEGFRSRCABL1HCK
SCHEMBL16886162 0.91 BTK (0.52) PIK3CDEGFRSRCABL1HCK
SCHEMBL16886157 0.86 BTK (0.51) BTK
SCHEMBL16886161 0.86 PIK3CD (0.50) PIK3CDEGFRSRCABL1HCK
SCHEMBL15613543 0.85 SRC (0.48) PIK3CDEGFRSRCABL1HCK
SCHEMBL16886156 0.85 BTK (0.60) PIK3CDEGFRSRCABL1HCK
SCHEMBL16886173 0.85 BTK (0.50) PIK3CDEGFRSRCABL1HCK
SCHEMBL15613519 0.84 CSNK1A1 (0.49) PIK3CDEGFRSRCABL1HCK
SCHEMBL16886204 0.84 BTK (0.49) PIK3CDEGFRSRCABL1HCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK PIK3CD 357/4885EGFR 521/4885SRC 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback